ATE141329T1 - Rekombinante antikörper spezifisch für einen wachstumsfaktor-rezeptor - Google Patents

Rekombinante antikörper spezifisch für einen wachstumsfaktor-rezeptor

Info

Publication number
ATE141329T1
ATE141329T1 AT92810056T AT92810056T ATE141329T1 AT E141329 T1 ATE141329 T1 AT E141329T1 AT 92810056 T AT92810056 T AT 92810056T AT 92810056 T AT92810056 T AT 92810056T AT E141329 T1 ATE141329 T1 AT E141329T1
Authority
AT
Austria
Prior art keywords
chain variable
variable domain
dna
recombinant antibodies
growth factor
Prior art date
Application number
AT92810056T
Other languages
English (en)
Inventor
Winfried Stephan Dr Wels
Nancy E Dr Hynes
Ina-Maria Harwerth
Bernd Dr Groner
Norman Dr Hardman
Markus Zwickl
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of ATE141329T1 publication Critical patent/ATE141329T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92810056T 1991-02-05 1992-01-27 Rekombinante antikörper spezifisch für einen wachstumsfaktor-rezeptor ATE141329T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91810079 1991-02-05

Publications (1)

Publication Number Publication Date
ATE141329T1 true ATE141329T1 (de) 1996-08-15

Family

ID=8208816

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92810056T ATE141329T1 (de) 1991-02-05 1992-01-27 Rekombinante antikörper spezifisch für einen wachstumsfaktor-rezeptor

Country Status (10)

Country Link
EP (1) EP0502812B1 (de)
JP (1) JP3415171B2 (de)
AT (1) ATE141329T1 (de)
AU (1) AU662311B2 (de)
CA (1) CA2060544C (de)
DE (1) DE69212671T2 (de)
DK (1) DK0502812T3 (de)
ES (1) ES2091438T3 (de)
GR (1) GR3020809T3 (de)
IE (1) IE72959B1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
JPH08507686A (ja) * 1993-03-09 1996-08-20 アボツト・ラボラトリーズ 遺伝子操作酵素及びそれらの診断アッセイ用結合体
IT1264083B1 (it) * 1993-12-10 1996-09-10 Enea Ente Nuove Tec Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
JP3742103B2 (ja) * 1994-05-02 2006-02-01 ベルント グロナー 二価のタンパク質、調製及び利用
EP0739984A1 (de) * 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalente Polypeptiden die mindestens zwei Bereichen enthalten
EP1516628B1 (de) * 1995-07-27 2013-08-21 Genentech, Inc. Stabile isotonische lyophilisierte Proteinzusammensetzung
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
CA2246429C (en) * 1996-03-27 2007-07-24 Genentech, Inc. Erbb3 antibodies
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
DE19735105A1 (de) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
WO2000069459A1 (en) 1999-05-14 2000-11-23 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1282443B1 (de) 2000-05-19 2009-09-02 Genentech, Inc. Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb-antagonisten
EP1521776A2 (de) 2002-07-04 2005-04-13 Oncomab Gmbh Neoplasma-spezifische antikörper und deren verwendungen
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
EP1812064A4 (de) 2004-11-19 2009-07-08 Cornell Res Foundation Inc Verwendung vaskulärer endothelwachstumsfaktor-rezeptor-1+-zellen bei der behandlung und überwachung von krebs und beim screening bei chemotherapie
TWI441646B (zh) 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
CN101163503B (zh) 2005-02-23 2013-05-08 健泰科生物技术公司 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
EP2899541A1 (de) 2007-03-02 2015-07-29 Genentech, Inc. Voraussage der Reaktion auf einen HRE-Dimerisationshemmer auf Basis niedriger HER3-Expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP2012507299A (ja) 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｇｈｔ標的分子およびその使用
CA2755640C (en) 2009-03-20 2018-05-22 Genentech, Inc. Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
EP2435071A1 (de) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulatoren für den her2-signalweg bei her2-exprimierenden patienten mit magenkrebs
CA2784211C (en) 2010-02-18 2019-12-24 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
EP2536432B1 (de) 2010-02-19 2018-08-08 Cornell University Verfahren zur behandlung demyelinisierender autoimmunerkrankungen und anderer autoimmun- oder entzündungserkrankungen
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
EP2785864A2 (de) 2011-11-30 2014-10-08 F. Hoffmann-La Roche AG Erbb3-mutationen bei krebs
EP2788500A1 (de) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identifizierung von non-respondern auf her2-inhibitoren
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
EP3454863A1 (de) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombinationstherapien zur behandlung von krebs
US20240101677A1 (en) 2021-01-27 2024-03-28 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0338745B1 (de) 1988-04-16 1995-03-01 Celltech Limited Verfahren zur Herstellung von Proteinen mittels rekombinanter DNA
AU3693389A (en) 1988-05-23 1989-12-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Cloned gene for expression of antibodies reacting with human ovarian cancer
JP2761543B2 (ja) 1988-08-17 1998-06-04 味の素株式会社 ヒト癌原遺伝子産物に対するモノクローナル抗体及びそれを産生するハイブリドーマ
EP0967277A3 (de) * 1988-09-06 2003-10-15 Xoma Corporation Herstellung chimärer antikörpern, teils aus der maus, teils aus dem mensch, spezifisch für humane tumorantigene
WO1990014357A1 (en) * 1989-05-19 1990-11-29 Genentech, Inc. Her2 extracellular domain
EP1362868A3 (de) * 1991-03-06 2004-02-11 MERCK PATENT GmbH Humanisierte und chimäre monoklonale Antikörper die den Rezeptor für epidermalen Wachstumfaktor (EGF-R) binden
US5514554A (en) * 1991-08-22 1996-05-07 Becton Dickinson And Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy

Also Published As

Publication number Publication date
ES2091438T3 (es) 1996-11-01
DE69212671T2 (de) 1997-03-13
EP0502812B1 (de) 1996-08-14
CA2060544C (en) 2002-12-03
GR3020809T3 (en) 1996-11-30
EP0502812A1 (de) 1992-09-09
AU662311B2 (en) 1995-08-31
JP3415171B2 (ja) 2003-06-09
AU1042192A (en) 1992-08-13
DK0502812T3 (da) 1996-09-02
IE72959B1 (en) 1997-05-07
IE920361A1 (en) 1992-08-12
CA2060544A1 (en) 1992-08-06
JPH05192183A (ja) 1993-08-03
DE69212671D1 (de) 1996-09-19

Similar Documents

Publication Publication Date Title
DE69212671D1 (de) Rekombinante Antikörper spezifisch für einen Wachstumsfaktor-Rezeptor
ATE366747T1 (de) Menschliche monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor
IL93118A0 (en) Expression vectors,cells transformed thereby and their use in the production of chimeric monoclonal antibodies
ATE504601T1 (de) Anti-cd3-antikörper zur verwendung zur induzierung von immunsuppression
HU9402823D0 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
DE3687736D1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
ATE316137T1 (de) Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
ATE247168T1 (de) Humanisierte monoklonale antikörper
DE69724428D1 (de) Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
ATE166883T1 (de) Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
ZA9210006B (en) Anti-human IgE monoclonal antibodies.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
CY1107163T1 (el) Συνδεδεμενα με γαγγλιοζιτη ανασυνδυασμενα αντισωματα και η χρησιμοποιηση αυτων στη διαγνωση και θεραπευτικη αγωγη ογκων

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee